Question: is sipuleucel-t a checkpoint inhibitor?
Answer: This efficient strategy of checkpoint blockade represents one of the main oncological breakthroughs, with remarkable clinical durable responses and survival advantages observed in several cancer types. To date, sipuleucel-T (an autologous cellular immunotherapy) is the only approved immunotherapy for PC patients.